

*Tackling health challenges in
internationally linked research hubs 2025:*

From Immune Activation to Toxicity: Challenges of Cancer Immunotherapies

24th September 2025



9am-1.30pm



**Institut de Recherche en Cancérologie de Montpellier
(IRCM), conference room**

208 avenue des Apothicaires, 34000 Montpellier

Simultaneous French-English translation available



Programme

9h

OPENING SESSION

- Niels Bovenschen, Sonia Cantel, Sandra Crnko and Gilles Subra Research Hubs Module UU-UM Coordinators
- François Pierrot VP-RI UM
- David Azria Director of SIRIC Montpellier Cancer
- Guillaume Cartron (CHU Montpellier) « General picture of cancer and immunotherapies: context and challenges »

9h45

CLINICAL OVERVIEW

Focus Activation/ Resistance :

- Stanislas Quesada (ICM) - « Dissecting tumor heterogeneity in endometrial cancers to predict IO sensitivity »

Focus Toxicity:

- Monique Minnema (UMC Utrecht) - « Immunotherapy in hematological cancers: Focus on common toxicities »

Focus Emerging therapies

- Maria Kfoury (Institut Paoli Calmette)

10h30

PATIENT PERSPECTIVE

Associations - The care pathway: the patient's point of view

- Alexandre Brutti Association LuCE / PeR-MRPC : actions in Europe - serious game Mon Immuno
- Harry Verbunt Association DiCE
- Pascale Beloni Association Imagyn
- Yann Bizien Advocate, Cure 51 patient's committee manager, « Living with treatment toxicity: a patient's perspective on immunotherapy »

11h10

COFFEE BREAK

11h30

RESEARCH STAKES

Emerging Tools

- William Jacot and Nathalie Bonnefoy Tribute to Marie-Alix Poul
- Nathalie Bonnefoy (IRCM) - « CD39 a novel therapeutic target in cancer Immunotherapy »
- Matthijs Monnikhof (University of Utrecht) - « Therapeutic Targeting of CD155/ TIGIT and PD-L1/PD-1 Immune Checkpoints Potentiates NK Cell-mediated Cytotoxicity in Medulloblastoma »
- Valérie Zimmermann (IGMM) - « CAR-T cell therapy limitations »
- Victor Peperzak (UMC Utrecht) (Online) - « Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation »
- Julien Faget (IRCM) - « R NA-based anti-cancer vaccine, why could it change patient's care? »
- Rene van Nostrum (Utrecht) - « Cancer immunotherapy: Nanogels for the delivery of tumor-specific antigen »
- Julien Dubois (ICM) - « Radiolabeling of therapeutic cells (CAR T-cells, NK cells, MSC...) : a powerful tool for understanding, optimizing, and ensuring the safety of adoptive cell therapies »
- Marie Morille (IHU Immune4Cure/ IRMB) - « When polymers meet Extracellular Vesicle (EVs): interest for in vivo administration and tumor accumulation »

13h

ROUND TABLE

From basics to real effects

Chairs: Gilles Subra, Cyril Sarrauste, Marie Morille

13h30

LUNCH
